ArticleJugan geon-gang gwa jilbyeong2024
[Korea 2022-2023 Influenza and Respiratory Viruses Laboratory Surveillance Report].
Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the 2022-2023 season, spanning 36 weeks in 2022 and 35 weeks in 2023, we performed real-time reverse transcription polymerase chain reaction tests on 15,009 respiratory specimens to analyze the causative pathogens and viral characteristics. Of these, 1,341 cases (8.9%) tested positive for influenza. Among positive cases, 1,085 cases (80.9%) were identified as A(H3N2), 211 (15.7%) as A(H1N1)pdm09, and 45 (3.4%) as type B. Genotype analysis confirmed similarity to vaccine strains. Furthermore, antigens from isolated influenza viruses exhibited effective neutralizing activity against vaccine strains and lacked resistance to oseltamivir, zanamivir, and peramivir treatments. Regarding other respiratory viruses, Rhinovirus was the most prevalent, detected in 1,978 cases (13.2%), followed by adenovirus (1,564 cases, 10.4%), metapneumovirus (1,456 cases, 9.7%), parainfluenza virus (1,430 cases, 9.5%), respiratory syncytial virus (1,139 cases, 7.6%), bocavirus (794 cases, 5.3%), and human coronavirus (742 cases, 4.9%). Following the relaxation of coronavirus disease 2019 control measurements, we observed a seasonal increase in respiratory viral diseases, highlighting the importance of national respiratory viral surveillance. Our department remains committed to closely monitoring causative pathogens and analyzing influenza virus trends and characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.